| Assessment Status | Rapid Review Complete |
| HTA ID | 23080 |
| Drug | Lipegfilgrastim |
| Brand | Lonquex® |
| Indication | Lipegfilgrastim is indicated in adults and in children two years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). Lipegfilgrastim is currently reimbursed on High Tech Drug Arrangement for use in adults and reimbursement is sought for children two years of age and older. |
| Assessment Process | |
| Rapid review commissioned | 21/12/2023 |
| Rapid review completed | 27/02/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that lipegfilgrastim not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
